JP2021502809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502809A5 JP2021502809A5 JP2020524841A JP2020524841A JP2021502809A5 JP 2021502809 A5 JP2021502809 A5 JP 2021502809A5 JP 2020524841 A JP2020524841 A JP 2020524841A JP 2020524841 A JP2020524841 A JP 2020524841A JP 2021502809 A5 JP2021502809 A5 JP 2021502809A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- mmdsc
- region
- methylation
- cpg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 8
- 230000011987 methylation Effects 0.000 claims 8
- 238000007069 methylation reaction Methods 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 108091093088 Amplicon Proteins 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 3
- 238000004458 analytical method Methods 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108091029523 CpG island Proteins 0.000 claims 1
- 108091029430 CpG site Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 108091036066 Three prime untranslated region Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000001369 bisulfite sequencing Methods 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000017858 demethylation Effects 0.000 claims 1
- 238000010520 demethylation reaction Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000001976 enzyme digestion Methods 0.000 claims 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017126248.2A DE102017126248B4 (de) | 2017-11-09 | 2017-11-09 | ERGIC1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesonderemonozytischem myeloid-abgeleiteten Suppressor-Zellen (mMDSCs) |
| DE102017126248.2 | 2017-11-09 | ||
| PCT/EP2018/080235 WO2019091942A1 (en) | 2017-11-09 | 2018-11-06 | ERGIC1 AS EPIGENETIC MARKER FOR THE IDENTIFICATION OF IMMUNE CELLS, IN PARTICULAR MONOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS (mMDSCs) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502809A JP2021502809A (ja) | 2021-02-04 |
| JP2021502809A5 true JP2021502809A5 (enExample) | 2021-08-19 |
Family
ID=64184067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524841A Pending JP2021502809A (ja) | 2017-11-09 | 2018-11-06 | 免疫細胞、特に単球性骨髄由来抑制細胞（ｍＭＤＳＣ）の同定のためのエピジェネティックマーカーとしてのＥＲＧＩＣ１ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11976327B2 (enExample) |
| EP (1) | EP3669005A1 (enExample) |
| JP (1) | JP2021502809A (enExample) |
| CN (1) | CN111315896A (enExample) |
| AU (1) | AU2018364335A1 (enExample) |
| DE (1) | DE102017126248B4 (enExample) |
| WO (1) | WO2019091942A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2714933A4 (en) | 2011-05-25 | 2014-12-31 | Univ Brown | METHODIZED METHOD FOR IDENTIFYING A CELL OR MIXING CELLS FOR THE PROGNOSIS AND DIAGNOSIS OF ILLNESSES AND FOR CELL HEALING THERAPIES |
| CN107941681B (zh) | 2013-04-19 | 2021-07-30 | 艾皮恩蒂斯有限公司 | 鉴定生物样品中定量细胞组成的方法 |
| AU2014284124B2 (en) | 2013-06-20 | 2020-03-12 | Immunexpress Pty Ltd | Biomarker identification |
| JP6750879B2 (ja) | 2014-04-14 | 2020-09-02 | イッスム・リサーチ・デベロプメント・カムパニー・オブ・ザ・ヘブリュー・ユニバシティー・オブ・エルサレム リミテッド | Ｄｎａの組織または細胞起源を決定するための方法およびキット |
-
2017
- 2017-11-09 DE DE102017126248.2A patent/DE102017126248B4/de active Active
-
2018
- 2018-11-06 EP EP18799716.8A patent/EP3669005A1/en active Pending
- 2018-11-06 CN CN201880071954.8A patent/CN111315896A/zh not_active Withdrawn
- 2018-11-06 US US16/762,534 patent/US11976327B2/en active Active
- 2018-11-06 WO PCT/EP2018/080235 patent/WO2019091942A1/en not_active Ceased
- 2018-11-06 AU AU2018364335A patent/AU2018364335A1/en not_active Abandoned
- 2018-11-06 JP JP2020524841A patent/JP2021502809A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jara-Acevedo et al. | Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications | |
| JP6189600B2 (ja) | Ｔ細胞受容体ｖ／ｄ／ｊ遺伝子内の反復配列によるクローン細胞の同定 | |
| EP3327141B1 (en) | Method for identifying the quantitative cellular composition in a biological sample | |
| Muthaiah et al. | Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates | |
| JP2018529345A5 (enExample) | ||
| JP2012511917A5 (enExample) | ||
| JP2018529346A5 (enExample) | ||
| CA2864192A1 (en) | Epigenetic marker for the identification of cd3cd4 positive t lymphocytes | |
| Weber | Biomarkers for checkpoint inhibition | |
| JP2018534910A5 (enExample) | ||
| JP2018529345A (ja) | 免疫細胞、特にｂ細胞の同定のためのエピジェネティックマーカーとしてのｌｒｐ５ | |
| KR20180007291A (ko) | 암 리스크를 검출하는 방법 | |
| JP4088694B2 (ja) | 造血器腫瘍の検査方法およびキット | |
| JP6543573B2 (ja) | ＣＤ８＋Ｔリンパ球、特にＣＤ８α及びβＴリンパ球の亜集団の同定用のエピジェネティック法 | |
| KR101832160B1 (ko) | 한국인 가족성 고콜레스테롤혈증에서 다유전자 기인성 | |
| CN108026577B (zh) | Mvd作为用于鉴定免疫细胞特别是cd56+nk细胞的表观遗传标志物 | |
| JP6113159B2 (ja) | ナチュラルキラー細胞を同定するエピジェネティックマーカー | |
| Genshaft et al. | Clinical implementation of single-cell RNA sequencing using liver fine needle aspirate tissue sampling and centralized processing captures compartment specific immuno-diversity | |
| JP2021502809A5 (enExample) | ||
| KR20240015624A (ko) | 게놈 전체 cfdna 단편화 프로파일을 이용한 암을 검출하는 방법 | |
| JP5009289B2 (ja) | Ｍａｌｔリンパ腫の検査方法及びキット | |
| JP2021502806A5 (enExample) | ||
| JP7019188B2 (ja) | ナチュラルキラー細胞機能の検査方法 | |
| JP7105460B2 (ja) | 成人ｔ細胞白血病／リンパ腫の検出方法 | |
| JP2021502809A (ja) | 免疫細胞、特に単球性骨髄由来抑制細胞（ｍＭＤＳＣ）の同定のためのエピジェネティックマーカーとしてのＥＲＧＩＣ１ |